Format

Send to

Choose Destination
Nat Med. 2015 Jan;21(1):81-5. doi: 10.1038/nm.3773. Epub 2014 Dec 22.

High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma.

Author information

1
Division of Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
2
Department of Clinical Oncology, Leiden University Medical Center, Leiden, the Netherlands.
3
AIMM Therapeutics B.V., Amsterdam, the Netherlands.
4
Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, United Kingdom.
5
Central Genomics Facility, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
6
Peptide Synthesis Facility, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
7
1] Division of Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. [2] Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.

Abstract

Tumor-specific neo-antigens that arise as a consequence of mutations are thought to be important for the therapeutic efficacy of cancer immunotherapies. Accumulating evidence suggests that neo-antigens may be commonly recognized by intratumoral CD8+ T cells, but it is unclear whether neo-antigen-specific CD4+ T cells also frequently reside within human tumors. In view of the accepted role of tumor-specific CD4+ T-cell responses in tumor control, we addressed whether neo-antigen-specific CD4+ T-cell reactivity is a common property in human melanoma.

PMID:
25531942
DOI:
10.1038/nm.3773
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center